News and Media
News and Media
Onxeo will publish its full-year results on April 24, 2023
April 21, 2023
Onxeo will publish its full-year results on April 14, 2023
March 14, 2023
Onxeo: report on the Extraordinary General Meeting of February 6, 2023
February 6, 2023
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
November 30, 2022
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
November 30, 2022
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
September 13, 2022
High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie
September 1, 2022
Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen
August 30, 2022
Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen
August 17, 2022
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures
July 29, 2022
Onxeo announces a Combined General Meeting on August 17, 2022
July 12, 2022
Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
June 30, 2022
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
June 16, 2022
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
April 7, 2022
Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
April 6, 2022
Press Release Signup
Subscribe to receive our Press Releases when they come out.
